Last Price$61.4(0.0%)
Market Cap$7,773.1M
6.5x
Industry median - 5.2x
5Y Historical average - 7.0x
1.9x
Industry median - 1.4x
5Y Historical average - 1.9x
FCF to Interest
25.9x
Industry median - (11.6x)
5Y Historical average - 16.7x
413.9%
Industry median - 4.2%
5Y Historical average - 768.2%
HALO Health Rating
HALO Health rating
6.7
HALO Health rating performance
HALO Financial Stability & Strength
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
FCF to Interest
Intangibles as % of Total Assets
Competing with HALO Financial Health
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Net Debt | Health score | Current ratio | Quick ratio | Net Debt to FCF | FCF to Interest | Intangibles as % of Total Assets | Total Debt to Equity |
$7,773.1M | $909.7M | 6.7 | 7.8x | 6.5x | 1.9x | 25.9x | 19.5% | 413.9% | |
$124.8B | ($4,366.4M) | 5.8 | 2.7x | 2.2x | 5.5x | (25.8x) | 3.7% | 10.7% | |
$77.0B | ($15.9B) | 6.6 | 33.5x | 29.7x | (4.4x) | 65.2x | 3.0% | 5.7% | |
$34.4B | N/A | 5.6 | N/A | N/A | N/A | (103.5x) | N/A | N/A | |
$30.7B | ($1,398.5M) | 6.9 | 2.8x | 2.6x | 32.8x | (0.3x) | 0.0% | 1,931.9% | |
$24.0B | (€16.5B) | 6.8 | 7.5x | 7.3x | 71.9x | (11.5x) | 3.5% | 1.3% | |
$14.5B | $5,841.4M | 4.7 | 1.4x | 1.4x | 2.1x | 12.3x | 0.0% | 73.6% | |
$13.8B | ($2,967.0M) | 6.9 | 5.2x | 4.8x | (2.7x) | 25.2x | 1.1% | 4.7% | |
$13.4B | ($535.0M) | 6.1 | 5.3x | 3.0x | (1.1x) | 38.5x | 3.7% | 10.7% | |
$13.3B | ($405.1M) | 6.8 | 10.2x | 9.9x | 2.9x | (16.4x) | 0.0% | 1.9% | |
$1,846.9M | ($1,600.5M) | 4.3 | 1.9x | 1.6x | 1.5x | N/A | 0.9% | 32.1% |
FAQ
What is the Halozyme Therapeutics, Inc. (HALO) quick ratio?
The Halozyme Therapeutics, Inc. (HALO) quick ratio is 6.5x, compared to the industry median of 5.2x and the 5-year historical average of 7.0x.
What is the Halozyme Therapeutics, Inc. (HALO) net debt to Free Cash Flow (FCF) ratio?
The Halozyme Therapeutics, Inc. (HALO) net debt to FCF ratio is 1.9x, compared to the industry median of 1.4x and the 5-year historical average of (1.9x).
What is Halozyme Therapeutics, Inc. (HALO) Free Cash Flow (FCF) to interest ratio?
Halozyme Therapeutics, Inc. (HALO) FCF to interest ratio is 25.9x, compared to the industry median of (11.6x) and the 5-year historical average of 16.7x.
What is the Halozyme Therapeutics, Inc. (HALO) total debt to equity ratio?
The Halozyme Therapeutics, Inc. (HALO) total debt to equity ratio is 413.9%, compared to the industry median of 4.2% and the 5-year historical average of 768.2%.